National Resilience

National Resilience

National Resilience was founded in 2020 by Rahul Singhvi, a former executive at Johnson & Johnson and Merck, alongside Harvard professor Gary Pisano as board chair. The company raised over $800M in its first two years from a syndicate that included ARCH Venture Partners, CPP Investments, and the Alaska Permanent Fund (per The Wall Street Journal, 2021). Its founding premise: the COVID-19 pandemic had exposed a dangerous over-reliance on offshore contract manufacturing for critical medicines. The firm does not invest in drug discovery — it builds and operates Good Manufacturing Practice (GMP) facilities that produce biologics, vaccines, and gene therapies for biotech and pharmaceutical customers. Confirmed facilities include a campus in Alachua, Florida, and a partnership with the US Department of Defense to manufacture pandemic-response vaccines. Resilience also acquired the Boston-area manufacturing operations of Sanofi in 2021 to expand its capacity (per Sanofi press release, 2021). Resilience employs more than a dozen PhD-level scientists and operates facilities in Massachusetts, Florida, Quebec, and California. In March 2023, the company announced a strategic collaboration with the US Biomedical Advanced Research and Development Authority (BARDA) to build an integrated manufacturing network for medical countermeasures (per BARDA, March 2023). Resilience's structural differentiator is its focus on end-to-end biomanufacturing rather than drug development — it operates as a services company, not a therapeutics firm. That model means it does not compete with its own customers for product revenues, and it can serve multiple sponsors from a single facility. Its success will turn on whether it can maintain high utilization rates and GMP compliance across a distributed network of aging pharma plants.